Advertisement
Screener

PDS Biotechnology Corp (PDSB) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.7 / 5 stars · 20/59 Roast Me

PDS Biotechnology Corp Net Cash Provided by (Used in) Investing Activities, Continuing Operations

PDS Biotechnology Corp (PDSB) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$89.28 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-03.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-03

  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$89.28K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$347.30K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$144.09K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$118.03K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$686.71K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.31M.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$884.79K.
  • PDS Biotechnology Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$136.89K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2017-03-31-$89.28K
10-Q · filed 2017-05-03
-$436.58K
derived: sum of 2 quarters · filed 2017-05-03
-$580.67K
derived: sum of 3 quarters · filed 2017-05-03
-$698.70K
derived: sum of 4 quarters · filed 2017-05-03
2016-12-31-$347.30K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
-$491.39K
derived: sum of 2 quarters · filed 2017-03-02
-$609.42K
derived: sum of 3 quarters · filed 2017-03-02
-$686.71K
10-K · filed 2017-03-02
2016-09-30-$144.09K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01
-$262.12K
derived: sum of 2 quarters · filed 2016-11-01
-$339.41K
10-Q · filed 2016-11-01
-$845.07K
derived: sum of 4 quarters · filed 2017-05-03
2016-06-30-$118.03K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$195.32K
10-Q · filed 2016-08-03
-$700.98K
derived: sum of 3 quarters · filed 2017-05-03
-$1.05M
derived: sum of 4 quarters · filed 2017-05-03
2016-03-31-$77.29K
10-Q · filed 2017-05-03
-$582.95K
derived: sum of 2 quarters · filed 2017-05-03
-$935.20K
derived: sum of 3 quarters · filed 2017-05-03
-$1.30M
derived: sum of 4 quarters · filed 2017-05-03
2015-12-31-$505.66K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
-$857.92K
derived: sum of 2 quarters · filed 2017-03-02
-$1.22M
derived: sum of 3 quarters · filed 2017-03-02
-$1.31M
10-K · filed 2017-03-02
2015-09-30-$352.25K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01
-$713.35K
derived: sum of 2 quarters · filed 2016-11-01
-$799.42K
10-Q · filed 2016-11-01
-$1.42M
derived: sum of 4 quarters · filed 2017-03-02
2015-06-30-$361.09K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$447.17K
10-Q · filed 2016-08-03
-$1.07M
derived: sum of 3 quarters · filed 2017-03-02
2015-03-31-$86.08K
10-Q · filed 2016-05-03
-$705.72K
derived: sum of 2 quarters · filed 2017-03-02
2014-12-31-$619.64K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
-$884.79K
10-K · filed 2017-03-02
2014-09-30-$265.15K
10-Q · filed 2015-11-06
2013-12-31-$136.89K
10-K · filed 2016-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
SCYNEXIS INC (SCYX)United States$0.045B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
VERU INC. (VERU)United States$0.043B-3.93
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98